Dr. Gabriel Brooks is the Chief Medical Officer and leads the clinical function for all of Solid’s neuromuscular and cardiac programs.
Dr. Brooks has served as the Chief Medical Officer for Solid Biosciences since October 2023, having previously led the Rare Disease Research Unit at Pfizer as Rare Cardiovascular Therapeutic Area Head from September 2020.
Between September 2020 and September 2023, Dr. Brookes directed the translational development of a range of precision AAV gene therapies for dilated, arrhythmogenic, and hypertrophic cardiomyopathies, at Pfizer. Dr. Brooks also served as the vice president of research and development at 4D Molecular Therapeutics from November 2018 to September 2020, where he oversaw translational development of AAV gene therapies for Anderson Fabry, as well as the first-in-human dosing of AAV gene therapies for two ophthalmologic indications (choroideremia and X-linked retinitis pigmentosa). From April 2017 to November 2018, Dr. Brooks led a successful Phase III registrational study of flurpiridaz at GE Life Sciences, and led several cardiovascular clinical trials in rare and large market indications during his time at Gilead Life Sciences between August 2015 and April 2017.
Dr. Brooks received a Bachelor of Science in Biology from Carnegie Mellon University, a Doctor of Medicine from Cornell University, and a Master of Applied Sciences of Biostatistics and Epidemiology from the University of California, San Francisco. He completed his training in Internal Medicine at Johns Hopkins Hospital, Baltimore, and fellowships in general Cardiology and Advanced Imaging at the University of California, San Francisco.